Angiogenesis refers to a biological mechanism that regulates cell growth, in particular the process of establishing a blood supply that allows cells to reproduce. Being able to manipulate vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, and cut off the blood supply to tumors holds promise as a new approach to cancer therapy.

Apoptosis (programmed cell death) refers to the process by which cells self-destruct. Genentech scientists are investigating new ways to activate the apoptosis machinery in cancer cells as a means of attacking tumors.

Genentech's HER pathway expertise led to the development of Herceptin® and fuels the search for other therapeutic targets.

The Tumor Antigen Project includes molecules that are being evaluated in a number of cancers.

The Tumor Biology group is focused on the use of pre-clinical tumor models, cell-based assays, and clinical correlative studies to address questions relevant to the treatment of specific tumor types.

For more information about oncology at Genentech, see our Genentech BioOncology Media Kit.

Recruitment The Genentech Molecular Oncology group is looking for new scientists, research associates and postdocs. If interested please visit our Job Postings section.